SLC5A2 and type 2 diabetes mellitus: Regarding new treatment approaches, cardiovascular outcome trials in patients with type 2 diabetes have demonstrated the effectiveness of sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP1RA).